Giulia Masiero
A5050815815- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrhythmias and Treatments
- Acute Myocardial Infarction Research
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Aortic Disease and Treatment Approaches
- Cerebrovascular and Carotid Artery Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Peripheral Artery Disease Management
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Cardiac and Coronary Surgery Techniques
- Coronary Artery Anomalies
- Cardiovascular Issues in Pregnancy
- Nitric Oxide and Endothelin Effects
- Lipoproteins and Cardiovascular Health
- Cardiac Arrest and Resuscitation
- Cardiac Fibrosis and Remodeling
University of Padua
2016-2025
Policlinico San Matteo Fondazione
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Santa Maria Nuova Hospital
2024
Azienda Ospedaliera di Padova
2023
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
2018-2020
University of Utah
2020
Massachusetts General Hospital
2020
Erasmus MC
2020
Policlinico Universitario di Catania
2016-2019
Coronary access (CA) after transcatheter aortic valve replacement (TAVR) with supra-annular heart valves (THV) can be challenging. Specific Evolut R/Pro and Acurate Neo THVs orientations are associated reduced neo-commissure overlap coronary ostia, while SAPIEN 3 THV cannot oriented. With the ALIGN-ACCESS study (TAVR Commissural Alignment Followed by Access), we investigated impact of commissural alignment on feasibility CA TAVR.We performed angiography TAVR intra-annular 3, R/Pro, in 206...
Abstract Background and Aims Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary regurgitation (SMR). This study sought develop validate an artificial intelligence-derived risk score (EuroSMR score) predict 1-year outcomes (survival or survival + clinical improvement) SMR undergoing M-TEER. Methods An was developed from EuroSMR cohort (4172 428 treated M-TEER...
Background Transcatheter aortic valve replacement (TAVR)‐in‐TAVR is a possible treatment for transcatheter heart ( THV ) degeneration. However, the displaced leaflets of first will create risk plane RP under which passage coronary catheter be impossible. The aim our study was to evaluate potential impaired access CA after TAVR ‐in‐ . Methods and Results We prospectively performed angiography with different s in 137 consecutive patients, looking where crossed frame. If cannulation achieved...
Background— Invasive physiological assessment of myocardial bridges (MBs) is largely unsettled. Unlike fractional flow reserve (FFR), instantaneous wave–free ratio (iFR) a diastole-specific index. As such, its value might not be hampered by systolic pressure overshooting and negative gradient caused the compression tunneled coronary artery. Methods Results— We prospectively enrolled 20 patients with angina and/or positive noninvasive stress test, absence significant artery stenosis,...
Background Little is known about the impact of transcatheter mitral valve edge-to-edge repair on changes in left ventricular ejection fraction (LVEF) and effect an acute reduction LVEF prognosis. We aimed to assess after for both primary secondary regurgitation (PMR SMR, respectively), identify rates predictors reduction, estimate its Methods Results In this international multicenter registry, patients with PMR SMR undergoing were included. assessed (LVEFR), defined as relative decrease >15%...
Background: Conduction disturbances after transcatheter aortic valve replacement (TAVR) are often transient. Limited data exist on anatomic factors predisposing to pacemaker dependency TAVR. We sought assess the rate and possible predictors of Methods: Consecutive patients undergoing implantation up 30 days TAVR between May 2014 September 2019 were included. Baseline electrocardiographic, computed tomography, procedural characteristics collected, including depth membranous septum length, an...
Abstract Aims Acute mitral regurgitation (MR) in the setting of myocardial infarction (MI) may be result papillary muscle rupture (PMR). This condition is associated with high morbidity and mortality. We aim to evaluate feasibility transcatheter edge‐to‐edge valve repair (TEER) this acute setting. Methods results analysed data from International Registry MitraClip Mitral Regurgitation following Myocardial Infarction (IREMMI) 30 centres Europe, North America, middle east. included patients...
Data on the likelihood of left ventricle (LV) recovery in patients with severe LV dysfunction and aortic stenosis undergoing transcatheter valve implantation (TAVI) its prognostic value are limited.
Abstract Aims To report the incidence, predictors and clinical impact of device-related complications (DRCs) in IMP-IT (IMPella Mechanical Circulatory Support Device Italy) registry. Impella is percutaneous left ventricular assist devices, which provides mechanical circulatory support both cardiogenic shock (CS) high-risk coronary intervention (HR-PCI). The registry a multicentre evaluating trends use outcomes Italy. Methods results A total 406 patients have been included this registry:...
Background The impact of transcatheter aortic valve replacement (TAVR) leaflet design on long-term device performance is still unknown. This study sought to compare the clinical and hemodynamic outcomes intra- (IA) versus supra-annular (SA) TAVR designs up-to 10-years following implantation. Methods Consecutive patients with at least 5-years follow-up for severe symptomatic stenosis from June 2007 December 2016 were included. Bioprosthetic failure (BVF) deterioration (HVD) defined according...
Thrombotic and bleeding risks differ between sexes, partly in relation to distinct biology hormonal status, but also due differences age, comorbidities, body size at presentation. Women experience frequent fluctuations of prothrombotic status related menstrual cycle, use oral contraceptives, hormone replacement therapy, or menopause. Although clinical studies tend underrepresent women, available data consistently support sex-specific the baseline thrombotic haemorrhagic risks. Compared with...